STOCKHOLM, Jan. 18, 2022 /PRNewswire/ -- Medivir AB (Nasdaq
Stockholm: MVIR-B) today announced that the World Health
Organization (WHO) has selected the International Nonproprietary
Name (INN) fostroxacitabine bralpamide as the official generic name
for the company's patented candidate drug MIV-818, which is in
clinical development in primary liver cancer.
Medivir's main project, fostroxacitabine bralpamide (MIV-818),
is the company's proprietary candidate drug with a unique mechanism
of action, which makes fostroxacitabine bralpamide attractive to be
combined with a multitude of other drugs for the treatment of
hepatocellular carcinoma (HCC). In the ongoing study,
fostroxacitabine bralpamide is administered in two different
combinations, either with Lenvima®, a tyrosine kinase inhibitor, or
with Keytruda®, an anti-PD-1 checkpoint inhibitor.
- "We are now able to use a generic name for our candidate drug,
and for us that is an important step towards a product for the
treatment of HCC," said Magnus
Christensen, interim CEO and CFO of Medivir.
For further information, please contact:
Magnus Christensen, Interim CEO and
CFO, Medivir AB
Phone: +46 (0)8 5468 3100
E-mail: magnus.christensen@medivir.com
About fostroxacitabine bralpamide
Fostroxacitabine bralpamide (also named MIV-818) is a pro-drug
designed to selectively treat liver cancers and to minimize side
effects. It has the potential to become the first liver-targeted
and orally administered drug for patients with HCC and other forms
of liver cancer. Fostroxacitabine bralpamide has completed a phase
1b monotherapy study, and a
combination study in HCC was recently initiated.
About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related
deaths worldwide and hepatocellular carcinoma (HCC) is the most
common cancer that arises in the liver. Although existing therapies
for advanced HCC can extend the lives of patients, treatment
benefits are insufficient and death rates remain high. There are
42,000 patients diagnosed with primary liver cancer per year in the
US and current five-year survival is 11 percent. HCC is a
heterogeneous disease with diverse etiologies, and lacks defining
mutations observed in many other cancers. This has contributed to
the lack of success of molecularly targeted agents in HCC. The
limited overall benefit, taken together with the poor overall
prognosis for patients with intermediate and advanced HCC, results
in a large unmet medical need.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the
unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
fostroxacitabine bralpamide (MIV-818), a pro-drug designed to
selectively treat liver cancer cells and to minimize side
effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (Stockholm: MVIR-B) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-s-miv-818-obtains-the-international-nonproprietary-name-fostroxacitabine-bralpamide,c3487790
The following files are available for download:
|
https://mb.cision.com/Main/652/3487790/1521586.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/medivirs-miv-818-obtains-the-international-nonproprietary-name-fostroxacitabine-bralpamide-301462497.html
SOURCE Medivir
